Literature DB >> 14076167

CANADIAN THALIDOMIDE EXPERIENCE.

J F WEBB.   

Abstract

Data are presented on 115 children, including three sets of twins, born in Canada in 1961 and 1962 with congenital malformations associated with the use of thalidomide by their mothers in early pregnancy. The epidemiological method is described. Of the 115 children, 74 were alive at the time of reporting, 41 of these being severely handicapped; 8 had been stillborn; 33 had died. Limb involvement was usually bilateral, affecting the upper limbs alone in 42 cases, and the upper and lower limbs in 41. Of 112 mothers, only 60 had had the drug prescribed by the physician providing maternity care; 87 were estimated to have first taken the drug before their last menstrual period or within 56 days thereafter. A plea is made for the development of better methods of collecting information on the occurrence of congenital malformations, with the aid of practising physicians.

Entities:  

Keywords:  ABNORMALITIES, DRUG-INDUCED; CANADA; ECTROMELIA; FETAL DEATH; INFANT; INFANT MORTALITY; INFANT, NEWBORN; MATERNAL-FETAL EXCHANGE; PREGNANCY; STATISTICS; THALIDOMIDE; TOXICOLOGIC REPORT

Mesh:

Substances:

Year:  1963        PMID: 14076167      PMCID: PMC1921912     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  7 in total

1.  Phocomelia: report of three cases.

Authors:  F J COODIN; I A UCHIDA; C H MURPHY
Journal:  Can Med Assoc J       Date:  1962-10-06       Impact factor: 8.262

2.  [Thalidomide embryopathy. II. Results of individual anamnestic findings in the areas of inquiry of the universities of Bonn, Cologne, Muenster and Duesseldorf pediatric clinics].

Authors:  H WEICKER; K D BACHMANN; R A PFEIFFER; J GLEISS
Journal:  Dtsch Med Wochenschr       Date:  1962-08-17       Impact factor: 0.628

3.  Thalidomide and malformations in Liverpool.

Authors:  R W SMITHELLS
Journal:  Lancet       Date:  1962-06-16       Impact factor: 79.321

4.  A study of the German outbreak of phocomelia. The thalidomide syndrome.

Authors:  H B TAUSSIG
Journal:  JAMA       Date:  1962-06-30       Impact factor: 56.272

5.  Thalidomide and congenital abnormalities.

Authors:  A L SPEIRS
Journal:  Lancet       Date:  1962-02-10       Impact factor: 79.321

6.  Thalidomide and Anal Abnormalities.

Authors:  E J Ives
Journal:  Can Med Assoc J       Date:  1962-09-22       Impact factor: 8.262

7.  Association of thalidomide (Kevadon) with congenital anomalies.

Authors:  A E RODIN; L A KOLLER; J D TAYLOR
Journal:  Can Med Assoc J       Date:  1962-04-21       Impact factor: 8.262

  7 in total
  9 in total

1.  Status Report--Retracing the history of the early development of national chronic disease surveillance in Canada and the major role of the Laboratory Centre for Disease Control (LCDC) from 1972 to 2000.

Authors:  B C K Choi; D T Wigle; H Johansen; J Losos; M E Fair; E Napke; L J Anderson; J W Davies; K White; A B Miller; F C K Li; S Stachenko; J Lindsay; L A Gaudette; C Nair; I Levy; H Morrison; J Silins; F Bouchard; L Tonmyr; P J Villeneuve; L McRae; K C Johnson; R S Lane; A Probert
Journal:  Health Promot Chronic Dis Prev Can       Date:  2015-04       Impact factor: 3.240

2.  High-strength opioid formulations: the case for a ministerial recall.

Authors:  Matthew Herder; David Juurlink
Journal:  CMAJ       Date:  2018-12-03       Impact factor: 8.262

Review 3.  Regulating prescription drugs for patient safety: does Bill C-17 go far enough?

Authors:  Matthew Herder; Elaine Gibson; Janice Graham; Joel Lexchin; Barbara Mintzes
Journal:  CMAJ       Date:  2014-03-10       Impact factor: 8.262

4.  Have Current Systems of Pharmacovigilance Had Their Day?: THE "CON" SIDE.

Authors:  Christine M Bond
Journal:  Can J Hosp Pharm       Date:  2020-04-01

5.  Medical and psychosocial aspects of the habilitation of thalidomide children.

Authors:  M Mongeau; G Gingras; E D Sherman; B Hebert; J Hutchison; C Corriveau
Journal:  Can Med Assoc J       Date:  1966-08-27       Impact factor: 8.262

6.  Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice.

Authors:  Emma C Fink; Marie McConkey; Dylan N Adams; Saurav D Haldar; James A Kennedy; Andrew A Guirguis; Namrata D Udeshi; D R Mani; Michelle Chen; Brian Liddicoat; Tanya Svinkina; Andrew T Nguyen; Steven A Carr; Benjamin L Ebert
Journal:  Blood       Date:  2018-07-31       Impact factor: 25.476

Review 7.  Trial Watch: Lenalidomide-based immunochemotherapy.

Authors:  Michaela Semeraro; Erika Vacchelli; Alexander Eggermont; Jerome Galon; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-10-21       Impact factor: 8.110

8.  Antenatal sildenafil citrate treatment increases offspring blood pressure in the placental-specific Igf2 knockout mouse model of FGR.

Authors:  L J Renshall; E C Cottrell; E Cowley; C P Sibley; P N Baker; E B Thorstensen; S L Greenwood; M Wareing; M R Dilworth
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-12-06       Impact factor: 4.733

9.  Maternal factors, medications, and drug exposure in congenital limb reduction defects.

Authors:  U G Froster; P A Baird
Journal:  Environ Health Perspect       Date:  1993-10       Impact factor: 9.031

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.